A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)

European Journal of Cancer（2022）

引用 3|浏览14

暂无评分

摘要

•Feasibility of two dose schedules of regorafenib initial deintensification in Europe.•No improvement on the overall safety profiles was seen.•A reduction in the most relevant AEs was observed (fatigue and HFSR).•Efficacy was sustained across the experimental arms despite dose deintensification.

查看译文

关键词

Colorectal cancer,Drug administration schedule,Metastasis,Regorafenib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要